HAVCR2 and leukemia: Following transduction of the third-generation CAR (CAR-TIM-3) containing TIM-3 single-chain fragment variable (scFv), CD28, 4-1BB, and CD3ζ into human NK-92 cells, these engineered cells effectively recognize and target TIM-3-positive cells, exhibiting significant antitumor activity against various primary AML cell lines, successfully inhibiting in vitro leukemia clone proliferation while exerting minimal impact on hematopoietic stem progenitor cells.